Biocon FY26 Results: ₹16,927 Cr Revenue, 10% Dividend

Board meeting clears results and corporate actions

Biocon Ltd’s board met on May 7, 2026 to approve audited financial results for the year ended March 31, 2026, and to clear a set of strategic and governance items. Alongside the results, the board recommended a final dividend, approved a plan to buy a small residual stake in Biocon Biologics Limited (BBL), and proposed changes to auditors and board composition. The disclosures also laid out key dates for dividend eligibility and the company’s annual general meeting (AGM). For investors, the immediate focus is on two linked tracks: the FY26 performance and the timetable to complete the next step in BBL integration.

FY26 headline numbers reported in the filing summary

The material shared reports consolidated FY26 revenue of Rs 1,69,270 million, which is ₹16,927.0 crore (using ₹1 crore = Rs 10 million). It also references consolidated FY25 revenue of Rs 1,52,617 million, which is ₹15,261.7 crore. On profitability, one section of the shared text states consolidated net profit of Rs 14,294 million for FY26, which is ₹1,429.4 crore. Another section mentions consolidated net profit of Rs 3,688 million (₹368.8 crore) for the same year. Both figures appear in the provided material, and readers tracking the audited results will typically look to the company’s published financial statements and accompanying notes for the final, reconciled view.

Dividend recommendation: 10% or Re 0.50 per share

The board recommended a final dividend of 10%, which is stated as Re 0.50 per equity share. The face value per share is noted as Rs 5. The record date is July 3, 2026 to determine shareholder entitlement. The payout is scheduled on or before August 31, 2026, subject to shareholder approval at the AGM.

Key dates: record date, AGM, and payout window

Biocon scheduled its 48th AGM for August 6, 2026, where shareholders will vote on matters including the final dividend. If approved, the dividend is to be paid on or before August 31, 2026. The company also indicated a trading window closure from April 1, 2026 to May 9, 2026, with reopening on May 10, 2026, as part of insider trading compliance.

BBL integration: proposal to acquire ~2% more equity

A central strategic item was the approval to acquire approximately 2% equity in Biocon Biologics Limited, described as a material subsidiary. The consideration is stated as up to ₹330.73 crore, to be executed through a preferential issue or special share issuance. The stated intent is to integrate BBL and make it a wholly owned subsidiary. The material also notes that the proposed acquisition requires necessary shareholder and regulatory approvals, which makes the approval timeline a key dependency for completion.

Preferential issue terms disclosed for the transaction

The disclosed structure includes issuance of up to 87,92,317 equity shares of Biocon at an issue price of Rs 376.16 per share. The acquisition is described as buying remaining equity shares from employees and other shareholders through a share swap mechanism. The targeted completion date mentioned is June 30, 2026, with an explicit caveat that delays in approvals could impact the integration timeline.

Auditor change and governance refresh

The board appointed S. R. Batliboi & Associates LLP as the new statutory auditors for a five-year term, stated as 2026-2031, replacing the previous auditors. The board also approved multiple director appointments, including five Independent Directors and one Non-Executive Director. The independent director names listed include Rajiv Malik, Daniel Bradbury, Peter Baron Piot, Arun Suresh Chandavarkar, and Nivruti Rai, with an effective date of August 1, 2026. In addition, the company designated Dr. Anuj Goel (Chief Development Officer) and Susheel Umesh (Chief Commercial Officer – Emerging Markets) as Senior Management Personnel.

Employee incentives and investor communication

Biocon approved the “Biocon Unity Long Term Incentive Plan 2026,” described as a stock-based incentive framework for eligible employees of the company and its subsidiaries. Separately, an earnings conference call for analysts and investors was scheduled for May 8, 2026 at 09:00 hrs IST via Zoom, with recordings and transcripts to be made available within specified timelines.

Other regulatory and operational updates cited

The material also references Health Canada’s approval of two denosumab biosimilars on April 3, 2026, presented as an expansion of the company’s biosimilar portfolio. One standalone number “382.25” appears in the shared text, without additional context in the excerpt. Investors typically map such references to a prevailing market price at the time of compilation, but the excerpt does not specify the timestamp or exchange quote context.

Key facts table (as reported)

Why the BBL approvals matter for investors

The board’s stated objective is to make BBL a wholly owned subsidiary, and the additional ~2% acquisition is framed as part of that integration. Because the transaction requires shareholder and regulatory approvals, the timeline is not purely operational. The company’s own target of June 30, 2026 highlights that approvals and execution steps will be watched closely, particularly if the company plans to simplify structure and consolidate control of the biosimilars business.

Conclusion

Biocon’s May 7 board outcomes combined audited FY26 results, a proposed 10% final dividend, and the next step in increasing ownership of BBL through a preferential issue. The key dates now are July 3 (record date) and August 6 (AGM), while the BBL acquisition process remains contingent on approvals, with June 30, 2026 cited as the targeted completion date.